Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential...
-
Dublin, March 16, 2018 (GLOBE NEWSWIRE) -- The "Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024" report has been added to ...
-
Dublin, March 14, 2018 (GLOBE NEWSWIRE) -- The "Enteral Feeding Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report...
-
Dublin, March 13, 2018 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's ...
-
Company Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. Food and Drug Administration (FDA) April 30th Action DateEnrollment Complete in Phase 3 Trial for...
-
CHARLOTTETOWN, Île-du-Prince-Édouard, 05 mars 2018 (GLOBE NEWSWIRE) -- Crohn et Colite Canada souligne les mesures décisives prises le gouvernement de l’Île-du-Prince-Édouard pour...
-
CHARLOTTETOWN, Prince Edward Island, March 05, 2018 (GLOBE NEWSWIRE) -- Crohn’s and Colitis Canada is recognizing the Government of Prince Edward Island for taking decisive action to protect and...
-
REDWOOD CITY, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Reputation.com, the first and only complete Online Reputation Management (ORM) platform, today accelerated its category momentum with the...
-
Key 2017 results: Expansion of filgotinib franchise: Start of 8 new disease area trials Opt-in to co-promote in Europe Second and third platform successes: Halt of disease progression...
-
Key Highlights: Top-line results from the Phase III study with RHB-104 for Crohn’s disease expected in mid-2018Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori...